Literature DB >> 22969792

Evolution and complexity of micro RNA in the human brain.

Walter J Lukiw1.   

Abstract

Entities:  

Year:  2012        PMID: 22969792      PMCID: PMC3432495          DOI: 10.3389/fgene.2012.00166

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


× No keyword cloud information.
The discovery of small non-coding RNAs (sncRNAs), and the biological actions of these ribonucleotide entities in the developing, aging, and pathological human central nervous system (CNS) has opened a novel and fascinating vista into our appreciation of human brain epigenetics, the role of sncRNAs on homeostatic and pathogenic gene control, and the potential role of single stranded, 22&nt signals in shaping the transcriptome of the human CNS (Lukiw et al., 1992; Ambros, 2004, 2011; Lukiw, 2007; Lukiw and Pogue, 2007; Guo et al., 2010). Indeed, a major family of sncRNAs known as micro RNAs (miRNAs) has emerged as essential and critical regulators of gene expression in diverse neurobiological pathways in both health and disease. The primary mode of action of miRNAs is to bind to target ribonucleotide sequences in messenger RNAs (mRNAs), typically in their 3′ un-translated region (3′-UTR), resulting in a highly selective repression of the readout of that mRNA's genetic information (Lukiw, 2007; Guo et al., 2010; Ambros, 2011). Pathogenically up-regulated miRNAs can be considered an epigenetic mechanism to down-regulate specific mRNAs and their expression. Up-regulated miRNA in human brain-specific neurodegenerative disorders such as Alzheimer's disease (AD) may help explain the large number of essential brain gene messages observed to be significantly down-regulated in AD affected anatomical regions, such as in the temporal lobe neocortex (Brodmann area 22) and hippocampus, or in primary human brain cell cultures that are chronically subjected to AD-relevant stressors (Loring et al., 2001; Colangelo et al., 2002; Lukiw, 2004, 2012; Lukiw and Pogue, 2007; Sethi and Lukiw, 2009; Ginsberg et al., 2012; Lukiw and Alexandrov, 2012; Lukiw et al., 2012; Wang et al., 2012). While the total number of human miRNAs identified to date in all tissues numbers around 2000, the number of abundant human brain miRNAs is surprisingly far less; for example only about one-thirtieth of all so far identified human miRNAs are abundantly present in the human brain association neocortex (Table 1). Further, mathematical, bioinformatical, and nucleotide sequence analysis indicate that a 22&nt single stranded RNA composed of four different ribonucleotides (A, G, C, and U) may have as many as 1013 possible sequence combinations, so the fact that there typically only on the scale of ∼102 abundant miRNAs in any single human brain sample suggests a very high developmental and evolutionary selection pressure to utilize only specific miRNA oligonucleotide sequences that will yield neurobiologically useful miRNA–mRNA interactions (Lukiw, 2012; Lukiw and Alexandrov, 2012). Table 1 lists the 61 most abundant miRNAs found in a critically controlled pool of short post-mortem interval (PMI; <3&h; total N&=&21) human association neocortex (Brodmann area A22) indicating that only about 61 of 10. An additional interesting fact is that miRNAs are highly developmental stage-, tissue- and cell-specific, even in adjacent cell types, and mean abundance of these individual species may fluctuate as do the levels of transcription factors which regulate pre-miRNA transcription (Burmistrova et al., 2007; Lukiw and Pogue, 2007; Guo et al., 2010; Lukiw and Alexandrov, 2012). The stability, and hence persistence of action, of sncRNAs, and miRNA appear to follow the adenine-uracil (AU) element (ARE) rich rules as for mRNA stability, and the half-life of several brain abundant miRNAs has been observed to be surprisingly restricted (Sethi and Lukiw, 2009; Wang et al., 2012). For example, human brain miRNA half-lives have been estimated to range from about 30&min (miRNA-9) to about 3&h (miRNA-125b), so overall the generation of a new miRNA, its longevity and interdiction of translational processes may be relatively rapid neurogenetic process (Sethi and Lukiw, 2009). However, other biophysical and neurogenetic parameters such as miRNA secondary and tertiary structure, miRNA binding proteins, and other factors may significantly extend miRNA viability and action.
Table 1

Most abundant miRNAs in the human brain temporal lobe association neocortex; ranked by miRNA numerical designation; based on pooled data from .

hsa-let-7a-5phsa-miR-23b-3p
hsa-let-7b-5phsa-miR-23c
hsa-let-7chsa-miR-24-3p
hsa-let-7d-5phsa-miR-26a-5p
hsa-let-7f-5phsa-miR-26b-5p
hsa-let-7g-5phsa-miR-27a-3p
hsa-miR-100-5phsa-miR-27b-3p
hsa-miR-101-3phsa-miR-29a-3p
hsa-miR-103a-3phsa-miR-29b-3p
hsa-miR-107hsa-miR-29c-3p
hsa-miR-124-3phsa-miR-30a-5p
hsa-miR-125a-5phsa-miR-30b-5p
hsa-miR-125b-5phsa-miR-30c-5p
hsa-miR-126-3phsa-miR-30d-5p
hsa-miR-1273g-3phsa-miR-338-3p
hsa-miR-128hsa-miR-342-3p
hsa-miR-139-5phsa-miR-3665
hsa-miR-145-5phsa-miR-3960
has-miR-146a-5phsa-miR-4324
hsa-miR-151a-5phsa-miR-4454
hsa-miR-151bhsa-miR-4516
hsa-miR-16-5phsa-miR-451a
hsa-miR-181a-5phsa-miR-4787-5p
hsa-miR-181b-5phsa-miR-5001-5p
hsa-miR-181dhsa-miR-5100
hsa-miR-191-5phsa-miR-574-3p
hsa-miR-195-5phsa-miR-9-3p
hsa-miR-21-5phsa-miR-9-5p
hsa-miR-221-3phsa-miR-99a-5p
hsa-miR-222-3phsa-miR-99b-5p
hsa-miR-23a-3p

Note that miRNAs are developmentally and temporally regulated and may display variable abundance in different cells or cell types; larger sample sets need to be analyzed to research these abundance patterns; at this point we cannot exclude the abundance and complexity of other enriched miRNA species. See also Burmistrova et al. (.

Most abundant miRNAs in the human brain temporal lobe association neocortex; ranked by miRNA numerical designation; based on pooled data from . Note that miRNAs are developmentally and temporally regulated and may display variable abundance in different cells or cell types; larger sample sets need to be analyzed to research these abundance patterns; at this point we cannot exclude the abundance and complexity of other enriched miRNA species. See also Burmistrova et al. (. Another poorly understood layer of complexity in miRNA signaling is that several miRNAs may regulate a single mRNA in a neurogenetic control process known as miRNA convergence, and conversely, a single miRNA may interact with multiple mRNAs in a regulatory process known as miRNA divergence (Lukiw and Alexandrov, 2012). Multiple functioning, and sometimes overlapping, miRNA binding sites have been found, for example, in the 232&nt 3′-UTR of the human innate immune response regulator complement factor H (CFH) mRNA in the human brain and retina. Therefore a different repertoire of miRNAs might be used to regulate CFH expression in either of these related tissue types (Lukiw and Alexandrov, 2012; Lukiw et al., 2012). Indeed, overlapping of miRNA binding sites in the 3′-UTR of the same mRNA may be an evolutionary strategy to regulate specific gene expression via a common genetic signal in multiple and related cell types (Lukiw and Alexandrov, 2012; Lukiw et al., 2012). Anti-miRNA (antagomir, AM) approaches to these multiple miRNA binding sites in mRNA 3′-UTRs are currently redirecting our therapeutic perspectives to potentially yield novel and highly efficacious treatment strategies for brain diseases that have not yet been considered (Lukiw et al., 2008, 2012; Cui et al., 2010; Wang et al., 2012). It will be particularly interesting to analyze global miRNA–mRNA targeting and control patterns in the brain and CNS to further unravel this fascinating, evolutionarily selective regulatory networking. How individual sncRNA, miRNA, and mRNA complexity together become progressively altered in aging and disease, and their selective quenching using novel AM strategies should be of high therapeutic value in the homeostatic stabilization of miRNA complexity, and in the treatment of common, age-related degenerative disorders, both inside and outside of the central nervous system.
  18 in total

1.  A gene expression profile of Alzheimer's disease.

Authors:  J F Loring; X Wen; J M Lee; J Seilhamer; R Somogyi
Journal:  DNA Cell Biol       Date:  2001-11       Impact factor: 3.311

Review 2.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

3.  NF-кB-regulated micro RNAs (miRNAs) in primary human brain cells.

Authors:  Walter J Lukiw
Journal:  Exp Neurol       Date:  2011-11-23       Impact factor: 5.330

4.  Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease (AD) and in age-related macular degeneration (AMD).

Authors:  Walter J Lukiw; Bhattacharjee Surjyadipta; Prerna Dua; Peter N Alexandrov
Journal:  Int J Biochem Mol Biol       Date:  2012-03-20

Review 5.  Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain.

Authors:  Walter J Lukiw; Peter N Alexandrov
Journal:  Mol Neurobiol       Date:  2012-08       Impact factor: 5.590

Review 6.  MicroRNAs and developmental timing.

Authors:  Victor Ambros
Journal:  Curr Opin Genet Dev       Date:  2011-04-29       Impact factor: 5.578

7.  BC200 RNA in normal human neocortex, non-Alzheimer dementia (NAD), and senile dementia of the Alzheimer type (AD).

Authors:  W J Lukiw; P Handley; L Wong; D R Crapper McLachlan
Journal:  Neurochem Res       Date:  1992-06       Impact factor: 3.996

8.  MicroRNA in schizophrenia: genetic and expression analysis of miR-130b (22q11).

Authors:  O A Burmistrova; A Y Goltsov; L I Abramova; V G Kaleda; V A Orlova; E I Rogaev
Journal:  Biochemistry (Mosc)       Date:  2007-05       Impact factor: 2.487

9.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

10.  Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity.

Authors:  Hongyan Wang; Ming Chiu; Zhiliang Xie; Michael Chiu; Zhongfa Liu; Ping Chen; Shujun Liu; John C Byrd; Natarajan Muthusamy; Ramiro Garzon; Carlo M Croce; Guido Marcucci; Kenneth K Chan
Journal:  Mol Pharm       Date:  2012-05-23       Impact factor: 4.939

View more
  19 in total

Review 1.  Role of viruses, prions and miRNA in neurodegenerative disorders and dementia.

Authors:  Sayed Sartaj Sohrab; Mohd Suhail; Ashraf Ali; Mohammad Amjad Kamal; Azamal Husen; Fahim Ahmad; Esam Ibraheem Azhar; Nigel H Greig
Journal:  Virusdisease       Date:  2018-09-29

Review 2.  MicroRNA-dependent genetic networks during neural development.

Authors:  Daniel G Abernathy; Andrew S Yoo
Journal:  Cell Tissue Res       Date:  2014-05-28       Impact factor: 5.249

3.  Up-regulated Pro-inflammatory MicroRNAs (miRNAs) in Alzheimer's disease (AD) and Age-Related Macular Degeneration (AMD).

Authors:  Aileen I Pogue; Walter J Lukiw
Journal:  Cell Mol Neurobiol       Date:  2018-01-04       Impact factor: 5.046

Review 4.  Plant and Animal microRNAs (miRNAs) and Their Potential for Inter-kingdom Communication.

Authors:  Yuhai Zhao; Lin Cong; Walter J Lukiw
Journal:  Cell Mol Neurobiol       Date:  2017-09-06       Impact factor: 5.046

5.  Fission Impossible: Stabilized miRNA-Based Analogs in Neurodegenerative Disease.

Authors:  Walter J Lukiw
Journal:  Front Neurosci       Date:  2022-05-03       Impact factor: 5.152

6.  microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF).

Authors:  Peter N Alexandrov; Prerna Dua; James M Hill; Surjyadipta Bhattacharjee; Yuhai Zhao; Walter J Lukiw
Journal:  Int J Biochem Mol Biol       Date:  2012-12-24

Review 7.  MicroRNA (miRNA): sequence and stability, viroid-like properties, and disease association in the CNS.

Authors:  Aileen I Pogue; James M Hill; Walter J Lukiw
Journal:  Brain Res       Date:  2014-04-04       Impact factor: 3.252

8.  Differential RNA packaging into small extracellular vesicles by neurons and astrocytes.

Authors:  Xuan Luo; Renée Jean-Toussaint; Ahmet Sacan; Seena K Ajit
Journal:  Cell Commun Signal       Date:  2021-07-10       Impact factor: 5.712

9.  Antagonism of NF-κB-up-regulated micro RNAs (miRNAs) in sporadic Alzheimer's disease (AD)-anti-NF-κB vs. anti-miRNA strategies.

Authors:  Walter J Lukiw
Journal:  Front Genet       Date:  2013-05-01       Impact factor: 4.599

10.  Alzheimer's disease (AD) as a disorder of the plasma membrane.

Authors:  Walter J Lukiw
Journal:  Front Physiol       Date:  2013-02-15       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.